
    
      Patients were randomized to either standard therapy (i.e., chemotherapy + targeted therapy)
      or standard therapy combined with Bifico. We will provide patients with first-line,
      second-line and third-line treatment with full intervention, including maintenance treatment.
      The standard treatment regimen, first-line (FOLFOX regimen + cetuximab) : oxaliplatin 85mg/m2
      intravenous infusion 2 hours day1 + calcium leucofolate (LV) 400mg/m2 intravenous infusion 2
      hours day1 + 5-fluorouracil (5-fu) 400mg/m2 intravenous infusion day 1, and then 1200mg/
      (m2·day) ×2 days continuous intravenous infusion + cetuximab 500mg/m2 intravenous infusion
      over 2 hours day 1, repeat every 2 weeks. First-line treatment 4 to 6 months after the
      effective disease control or stable but still no radical surgery opportunity, can enter
      maintenance treatment: 5 - FU + LV (dose with a line), repeat every 2 weeks, or capecitabine
      oral 2 1250 mg/m2 / day day 1-14 + beacizumab 7.5 mg/kg intravenous day 1, repeat every 3
      weeks, or stop the systemic treatment, until a progression, and immediately to the next line
      treatment; Second-line (FOLFIRI regimen + bevacizumab) : irinotegam 180 mg/m2 iv infusion
      over 30-90min day 1 + LV 400mg/m2 iv infusion 2 hours day 1 + 5-fu400 mg/m2 iv infusion day
      1, then 1200mg/ (m2·day) ×2 days continuous intravenous infusion + bevacizumab 5mg/kg
      introvenious infusion day 1, repeat every 2 weeks. Third line: fuquinib 160mg oral 1/ day day
      1-21, repeat every 28 days, or regofenil 5mg oral 1/ day day 1-21, repeat every 28 days.
      Bifico 2g oral 3/ day, take the medicine daily.
    
  